Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license for its TransCon technology platform to develop treatments for metabolic and cardiovascular diseases. This strategic partnership will focus on developing long-acting treatments for obesity, type 2 diabetes, and other cardiovascular conditions.
Biotech company BioAge Labs, focused on developing treatments for metabolic diseases, has filed for an initial public offering (IPO) on the Nasdaq, aiming to raise up to $100 million. The company’s lead drug, Azelaprag, has shown promising results in preclinical studies and is being investigated in multiple Phase 2 trials for obesity and other metabolic conditions. BioAge also has a pipeline of NLRP3 inhibitors for neuroinflammatory diseases, with an IND application expected in the second half of 2025.
A comprehensive study by the Indian Council of Medical Research reveals a concerning prevalence of non-communicable metabolic diseases in various Indian states. The report, published in The Lancet Diabetes & Endocrinology, highlights the increasing prevalence of diabetes, hypertension, obesity, and dyslipidemia in India. The study’s findings emphasize the need for region-specific strategies to mitigate this growing public health issue.
